This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
intensive care | 400 |
blood pressure | 362 |
ng ml | 307 |
mg kg | 305 |
metabolic syndrome | 294 |
mean age | 293 |
significantly higher | 289 |
renal failure | 282 |
risk factors | 276 |
septic shock | 275 |
control group | 249 |
critically ill | 232 |
pg ml | 228 |
mg dl | 217 |
care unit | 217 |
insulin resistance | 209 |
reactive protein | 206 |
critical care | 204 |
renal function | 202 |
type diabetes | 198 |
two groups | 197 |
ill patients | 179 |
nephrotic syndrome | 174 |
organ failure | 165 |
ml min | 157 |
body weight | 154 |
present study | 148 |
significant difference | 141 |
statistically significant | 141 |
mechanical ventilation | 139 |
patients admitted | 139 |
significantly lower | 135 |
renal disease | 135 |
urinary tract | 125 |
blood glucose | 122 |
years old | 121 |
diabetes mellitus | 118 |
inflammatory response | 118 |
significant differences | 116 |
blood samples | 113 |
body mass | 111 |
kidney disease | 110 |
cardiac arrest | 108 |
apache ii | 107 |
significantly increased | 107 |
risk factor | 107 |
crp levels | 106 |
septic patients | 104 |
oxidative stress | 104 |
serum creatinine | 103 |
renal biopsy | 99 |
uric acid | 98 |
gene expression | 98 |
icu admission | 97 |
peripheral blood | 97 |
regression analysis | 96 |
respiratory failure | 95 |
acute respiratory | 93 |
logistic regression | 93 |
waist circumference | 93 |
adipose tissue | 92 |
mortality rate | 92 |
blood flow | 90 |
cohort study | 90 |
weight loss | 90 |
hospital mortality | 89 |
acute renal | 89 |
mass index | 87 |
observational study | 86 |
plasma levels | 86 |
interest reported | 86 |
university hospital | 86 |
glucose tolerance | 86 |
serum levels | 85 |
endothelial cells | 85 |
cardiovascular risk | 84 |
chronic renal | 83 |
ml kg | 83 |
severe sepsis | 83 |
kg day | 82 |
multiple organ | 81 |
acquired pneumonia | 81 |
retrospective study | 81 |
patients received | 80 |
patients without | 80 |
significantly associated | 80 |
statistical analysis | 80 |
acute phase | 79 |
nitric oxide | 78 |
necrosis factor | 78 |
organ dysfunction | 76 |
heart rate | 76 |
long term | 76 |
median age | 75 |
icu patients | 75 |
physical activity | 75 |
one patient | 74 |
stage renal | 73 |
lipid profile | 73 |
tract infection | 73 |
side effects | 72 |
clinical signs | 72 |
icu stay | 72 |
significant correlation | 71 |
care units | 71 |
arterial pressure | 71 |
disease severity | 69 |
heart failure | 69 |
significantly reduced | 68 |
healthy controls | 68 |
among patients | 68 |
significant increase | 67 |
patients undergoing | 67 |
group i | 67 |
replacement therapy | 66 |
renal transplantation | 66 |
tumor necrosis | 66 |
immune response | 65 |
performed using | 64 |
increased risk | 64 |
significantly different | 64 |
diabetic patients | 64 |
cardiovascular disease | 64 |
predictive value | 64 |
results suggest | 63 |
important role | 63 |
prospective study | 62 |
least one | 62 |
clinical course | 62 |
day mortality | 62 |
adult patients | 62 |
insulin sensitivity | 61 |
sofa score | 61 |
renal replacement | 61 |
glomerular filtration | 61 |
respiratory tract | 60 |
glucose levels | 60 |
cardiac surgery | 60 |
lung injury | 60 |
positive correlation | 59 |
respiratory distress | 59 |
coronary artery | 59 |
two patients | 59 |
hospital stay | 59 |
blood cell | 59 |
critical illness | 58 |
bone marrow | 58 |
chronic kidney | 58 |
high risk | 57 |
arterial blood | 57 |
mean arterial | 57 |
weight gain | 57 |
group ii | 57 |
white blood | 56 |
data suggest | 56 |
renal insufficiency | 56 |
filtration rate | 55 |
myocardial infarction | 55 |
total cholesterol | 54 |
study period | 53 |
measured using | 53 |
previous studies | 53 |
left ventricular | 53 |
systemic inflammatory | 53 |
cardiac output | 53 |
fasting glucose | 52 |
high levels | 52 |
results indicate | 52 |
whole blood | 51 |
within hours | 51 |
plasma glucose | 50 |
peritoneal dialysis | 49 |
end stage | 49 |
clinical trials | 49 |
ii score | 49 |
polymerase chain | 49 |
chain reaction | 49 |
adverse events | 49 |
cd cd | 49 |
healthy volunteers | 48 |
odds ratio | 48 |
immune system | 48 |
inclusion criteria | 48 |
myeloid cells | 47 |
significantly decreased | 47 |
patients treated | 47 |
distress syndrome | 47 |
standard deviation | 47 |
sectional study | 47 |
pediatric nephrology | 46 |
elderly patients | 45 |
creatinine ratio | 45 |
included patients | 45 |
linear regression | 45 |
animal models | 45 |
bacterial infection | 45 |
consecutive patients | 45 |
urinary protein | 45 |
complete remission | 44 |
fatty acids | 44 |
adhesion molecules | 44 |
emergency department | 44 |
receptor expressed | 44 |
hemorrhagic shock | 44 |
central venous | 44 |
significant reduction | 44 |
informed consent | 43 |
clinical trial | 43 |
dex group | 43 |
blood gas | 43 |
triggering receptor | 43 |
renal transplant | 43 |
mg ml | 42 |
brain injury | 42 |
gram negative | 42 |
may lead | 42 |
pct levels | 42 |
venous blood | 42 |
fasting blood | 42 |
clinical features | 42 |
higher levels | 42 |
study group | 42 |
significant decrease | 42 |
healthy children | 42 |
systolic blood | 42 |
trauma patients | 41 |
renal tubular | 41 |
prospective observational | 41 |
clinical outcomes | 41 |
heart disease | 41 |
diastolic blood | 41 |
determine whether | 41 |
study showed | 41 |
pediatric patients | 41 |
mechanically ventilated | 41 |
one year | 41 |
mrna expression | 41 |
therapeutic hypothermia | 40 |
statistical significance | 40 |
survival rate | 40 |
healthy dogs | 40 |
birth weight | 40 |
medical records | 40 |
crp level | 40 |
one hundred | 40 |
growth factor | 40 |
inflammatory markers | 39 |
clinical data | 39 |
family members | 39 |
multivariate analysis | 39 |
impaired glucose | 39 |
kidney injury | 39 |
tract infections | 39 |
inflammatory cytokines | 39 |
three groups | 39 |
normal range | 38 |
tolerance test | 38 |
primary outcome | 38 |
obese patients | 38 |
converting enzyme | 38 |
glucose metabolism | 38 |
clinical characteristics | 38 |
may contribute | 38 |
skeletal muscle | 38 |
previously reported | 38 |
data collection | 38 |
hospital discharge | 37 |
flow cytometry | 37 |
amino acid | 37 |
factors associated | 37 |
acute kidney | 37 |
study included | 37 |
patients showed | 37 |
iga nephropathy | 37 |
physical examination | 37 |
severe acute | 37 |
metabolic acidosis | 37 |
respiratory rate | 37 |
per day | 37 |
findings suggest | 36 |
monoclonal antibodies | 36 |
creatinine clearance | 36 |
first time | 36 |
severe covid | 36 |
time points | 36 |
assessed using | 36 |
analysis showed | 36 |
cell surface | 36 |
retrospective cohort | 36 |
glycemic control | 36 |
cytokine production | 35 |
four patients | 35 |
body fat | 35 |
intervention group | 35 |
fat diet | 35 |
beneficial effects | 35 |
family history | 35 |
artery disease | 35 |
mononuclear cells | 34 |
mortality rates | 34 |
independent risk | 34 |
first days | 34 |
lupus nephritis | 34 |
old boy | 34 |
pilot study | 34 |
coronavirus disease | 34 |
study episodes | 34 |
controlled trial | 34 |
healthy subjects | 34 |
segmental glomerulosclerosis | 34 |
time pcr | 34 |
blood cells | 34 |
urine samples | 33 |
mean duration | 33 |
type ii | 33 |
abdominal obesity | 33 |
first hours | 33 |
age years | 33 |
receiver operating | 33 |
coronary angiography | 33 |
year period | 33 |
roc curve | 33 |
acute rejection | 33 |
poor outcome | 33 |
novel coronavirus | 33 |
data indicate | 33 |
mitral valve | 33 |
blood loss | 32 |
severe pneumonia | 32 |
oral glucose | 32 |
oxygen saturation | 32 |
natriuretic peptide | 32 |
dmsa scan | 32 |
bacterial infections | 32 |
th percentile | 32 |
alport syndrome | 32 |
recent studies | 32 |
wistar rats | 32 |
interquartile range | 32 |
month period | 32 |
graft function | 32 |
antibiotic therapy | 32 |
negative correlation | 32 |
higher risk | 32 |
ventilated patients | 32 |
retrospective analysis | 31 |
confidence interval | 31 |
mm hg | 31 |
obese subjects | 31 |
six patients | 31 |
cell count | 31 |
soluble triggering | 31 |
results show | 31 |
early diagnosis | 31 |
kidney transplantation | 31 |
tnf production | 31 |
differ significantly | 31 |
icu mortality | 31 |
type diabetic | 31 |
focal segmental | 31 |
patients underwent | 31 |
significantly correlated | 31 |
randomized controlled | 30 |
cord uid | 30 |
lower respiratory | 30 |
renal diseases | 30 |
ae years | 30 |
old girl | 30 |
doc id | 30 |
food intake | 30 |
upper respiratory | 30 |
exclusion criteria | 30 |
systematic review | 30 |
study population | 30 |
renal dysfunction | 30 |
increased significantly | 30 |
results showed | 30 |
inflammatory mediators | 30 |
receptor antagonist | 30 |
increased mortality | 30 |
average age | 30 |
decreased significantly | 30 |
tidal volume | 30 |
study aimed | 30 |
arterial hypertension | 30 |
severe disease | 30 |
operating characteristic | 29 |
thermal injury | 29 |
th day | 29 |
poor prognosis | 29 |
clinical practice | 29 |
icu discharge | 29 |
infectious diseases | 29 |
case report | 29 |
acute pancreatitis | 29 |
three patients | 29 |
hospital admission | 29 |
ang ii | 29 |
monoclonal antibody | 29 |
renal scarring | 29 |
low dose | 29 |
demographic data | 29 |
wbc count | 29 |
medical center | 29 |
respiratory viruses | 29 |
control groups | 29 |
organ damage | 29 |
surgical patients | 29 |
bronchoalveolar lavage | 29 |
high prevalence | 29 |
higher mortality | 29 |
may play | 29 |
patients receiving | 29 |
fasting plasma | 29 |
respiratory virus | 29 |
high dose | 29 |
may also | 28 |
endothelial cell | 28 |
lung tissue | 28 |
groups according | 28 |
clinical outcome | 28 |
study shows | 28 |
patients died | 28 |
host defense | 28 |
public health | 28 |
also found | 28 |
epithelial cells | 28 |
plasma concentrations | 28 |
nervous system | 28 |
newly diagnosed | 28 |
beneficial effect | 28 |
serum albumin | 28 |
response syndrome | 28 |
metabolic control | 28 |
laboratory tests | 27 |
density lipoprotein | 27 |
hospital cardiac | 27 |
bacterial translocation | 27 |
liver disease | 27 |
analysis revealed | 27 |
correlation coefficient | 27 |
disease activity | 27 |
steroid therapy | 27 |
tissue injury | 27 |
immune function | 27 |
author funder | 27 |
ug ml | 27 |
insulin secretion | 27 |
significant association | 27 |
high mortality | 27 |
renal involvement | 27 |
primary care | 27 |
cd cells | 27 |
blood transfusion | 27 |
traumatic brain | 27 |
granted medrxiv | 27 |
major surgery | 27 |
protein excretion | 27 |
group received | 27 |
bariatric surgery | 27 |
clinically relevant | 27 |
placebo group | 27 |
negative predictive | 27 |
term outcome | 27 |
recombinant human | 27 |
cell proliferation | 26 |
abdominal surgery | 26 |
protective effect | 26 |
determined using | 26 |
showed significant | 26 |
inflammatory responses | 26 |
survival time | 26 |
obese children | 26 |
high fat | 26 |
copyright holder | 26 |
regression model | 26 |
significantly improved | 26 |
vesicoureteral reflux | 26 |
endothelial dysfunction | 26 |
median time | 26 |
preliminary results | 26 |
class ii | 26 |
clinical studies | 26 |
one case | 26 |
total body | 26 |
viral infection | 26 |
single center | 26 |
serum concentrations | 26 |
overweight obese | 26 |
systemic inflammation | 26 |
laboratory data | 26 |
hospitalized patients | 26 |
blood levels | 26 |
animal model | 26 |
general hospital | 26 |
significantly elevated | 25 |
fluid resuscitation | 25 |
immune cells | 25 |
body surface | 25 |
commonly used | 25 |
associated pneumonia | 25 |
patients developed | 25 |
united kingdom | 25 |
crp values | 25 |
ex vivo | 25 |
widely used | 25 |
may result | 25 |
serum samples | 25 |
blood sample | 25 |
proinflammatory cytokines | 25 |
adverse effects | 25 |
prognostic value | 25 |
tissue damage | 24 |
cell types | 24 |
insulin levels | 24 |
chest pain | 24 |
reperfusion injury | 24 |
lipid peroxidation | 24 |
prospective cohort | 24 |
plasma leptin | 24 |
important factor | 24 |
within days | 24 |
acute myocardial | 24 |
amino acids | 24 |
gestational age | 24 |
body temperature | 24 |
surface area | 24 |
patient safety | 24 |
significant improvement | 24 |
western blot | 24 |
body composition | 24 |
growth hormone | 24 |
blood culture | 24 |
diabetic nephropathy | 24 |
autosomal recessive | 24 |
fatty liver | 24 |
urine culture | 24 |
red blood | 24 |
kg min | 24 |
animal studies | 24 |
lps challenge | 24 |
square test | 24 |
diagnostic performance | 24 |
dent disease | 23 |
viral infections | 23 |
studies suggest | 23 |
gene polymorphism | 23 |
transplant recipients | 23 |
peritoneal macrophages | 23 |
investigate whether | 23 |
renal damage | 23 |
independently associated | 23 |
normal values | 23 |
arterial stiffness | 23 |
urine output | 23 |
invasive ventilation | 23 |
levels showed | 23 |
mast cell | 23 |
grade iii | 23 |
ae vs | 23 |
also significantly | 23 |
made available | 23 |
high blood | 23 |
liver transplantation | 23 |
saps ii | 23 |
independent predictor | 23 |
protein intake | 23 |
health care | 23 |
statistical analyses | 23 |
slit diaphragm | 23 |
cell death | 23 |
sample size | 23 |
inflammatory process | 23 |
lung disease | 23 |
blood cultures | 23 |
healthy individuals | 23 |
five patients | 23 |
ethics committee | 23 |
term follow | 23 |
dm patients | 23 |
kidney function | 23 |
cell line | 23 |
lymph nodes | 23 |
molecular mechanisms | 23 |
continuous variables | 23 |
regression models | 23 |
young adults | 23 |
positively correlated | 23 |
fat mass | 22 |
neurological outcome | 22 |
liver failure | 22 |
diabetic subjects | 22 |
diagnostic criteria | 22 |
univariate analysis | 22 |
graft survival | 22 |
computed tomography | 22 |
study suggests | 22 |
morbidly obese | 22 |
function tests | 22 |
metabolic risk | 22 |
interstitial fibrosis | 22 |
elevated crp | 22 |
pleural effusion | 22 |
normal renal | 22 |
sepsis syndrome | 22 |
analyzed using | 22 |
also measured | 22 |
four groups | 22 |
laboratory findings | 22 |
clinical presentation | 22 |
renal impairment | 22 |
protein levels | 22 |
patients aged | 22 |
world health | 22 |
baseline characteristics | 22 |
negative sepsis | 22 |
mycophenolate mofetil | 22 |
care patients | 22 |
united states | 22 |
brain tissue | 22 |
blood mononuclear | 22 |
cytokine release | 22 |
host response | 22 |
control animals | 22 |
oxygen delivery | 22 |
two different | 22 |
mean ae | 22 |
burn injury | 22 |
negative bacteria | 22 |
teaching hospital | 22 |
injury severity | 21 |
studied patients | 21 |
adverse outcomes | 21 |
per patient | 21 |
confidence intervals | 21 |
months later | 21 |
serum il | 21 |
invasive mechanical | 21 |
investigated whether | 21 |
disease progression | 21 |
patients suffering | 21 |
visceral fat | 21 |
vascular resistance | 21 |
scoring system | 21 |
exact test | 21 |
three times | 21 |
stimulating factor | 21 |
blood sugar | 21 |
levels increased | 21 |
medrxiv preprint | 21 |
study design | 21 |
international license | 21 |
pulmonary artery | 21 |
age group | 21 |
inhalation injury | 21 |
lavage fluid | 21 |
wound healing | 21 |
cardiac index | 21 |
significantly greater | 21 |
obese women | 21 |
first year | 21 |
cardiovascular diseases | 21 |
animal health | 21 |
days later | 20 |
multiple linear | 20 |
treatment group | 20 |
results demonstrate | 20 |
care bundle | 20 |
ejection fraction | 20 |
cytokine storm | 20 |
cytokine levels | 20 |
van het | 20 |
platelet count | 20 |
mg day | 20 |
organ injury | 20 |
adhesion molecule | 20 |
dependent manner | 20 |
acute pyelonephritis | 20 |
shiny app | 20 |
significant positive | 20 |
energy expenditure | 20 |
atrial fibrillation | 20 |
commercially available | 20 |
categorical variables | 20 |
major cause | 20 |
abdominal sepsis | 20 |
sepsis patients | 20 |
children aged | 20 |
mean follow | 20 |
different types | 20 |
well known | 20 |
minimal change | 20 |
serum leptin | 20 |
median follow | 20 |
normal blood | 20 |
infectious complications | 20 |
group compared | 20 |
hypertensive patients | 20 |
observation period | 20 |
healthy control | 20 |
single centre | 20 |
care medicine | 20 |
complement activation | 20 |
day length | 20 |
electron microscopy | 20 |
prospective studies | 20 |
respiratory syncytial | 20 |
angiotensin converting | 20 |
uremic syndrome | 20 |
risk stratification | 20 |
patients required | 20 |
fatty acid | 20 |
urine protein | 20 |
antibiotic treatment | 20 |
leptin levels | 20 |
range proteinuria | 20 |
molecular weight | 20 |
glucose level | 20 |
clinical examination | 20 |
seven patients | 20 |
hdl cholesterol | 20 |
extracellular matrix | 20 |
days post | 20 |
os max | 19 |
normal glucose | 19 |
medical university | 19 |
membrane oxygenation | 19 |
pao fio | 19 |
central obesity | 19 |
transplant patients | 19 |
steroid resistant | 19 |
time course | 19 |
randomly selected | 19 |
kidney transplant | 19 |
large number | 19 |
common cause | 19 |
blood transfusions | 19 |
creatinine level | 19 |
severity scores | 19 |
nine patients | 19 |
abdominal pain | 19 |
independent predictors | 19 |
failure assessment | 19 |
ckd stage | 19 |
multiple trauma | 19 |
lipoprotein cholesterol | 19 |
urea nitrogen | 19 |
chronic diseases | 19 |
inflammatory reaction | 19 |
well tolerated | 19 |
cardiac function | 19 |
normal weight | 19 |
three different | 19 |
control study | 19 |
infected patients | 19 |
cardiovascular events | 19 |
treated patients | 19 |
salt wasting | 19 |
treated animals | 19 |
lg ml | 19 |
high doses | 19 |
biochemical parameters | 19 |
lymphocyte percentage | 19 |
chronic disease | 19 |
decision making | 19 |
may help | 19 |
smooth muscle | 19 |
plasma samples | 19 |
microscopic hematuria | 19 |
pulmonary disease | 19 |
two years | 19 |
partial remission | 19 |
treatment groups | 19 |
underlying disease | 19 |
real time | 19 |
reactive oxygen | 19 |
total number | 19 |
similar results | 19 |
fasting insulin | 19 |
survival rates | 18 |
kidney biopsy | 18 |
nutritional status | 18 |
differential diagnosis | 18 |
early detection | 18 |
year old | 18 |
financial support | 18 |
metabolic disorders | 18 |
postmenopausal women | 18 |
growth retardation | 18 |
metabolic abnormalities | 18 |
eight patients | 18 |
free radicals | 18 |
activated protein | 18 |
syncytial virus | 18 |
ae sd | 18 |
written informed | 18 |
congestive heart | 18 |
respiratory syndrome | 18 |
aged years | 18 |
postoperative period | 18 |
infectious disease | 18 |
influenza virus | 18 |
positive patients | 18 |
music therapy | 18 |
study entry | 18 |
short term | 18 |
analysed using | 18 |
renal injury | 18 |
nephrotic range | 18 |
highly significant | 18 |
basement membrane | 18 |
aki stage | 18 |
model assessment | 18 |
acute lung | 18 |
dawley rats | 18 |
high level | 18 |
complement system | 18 |
gel electrophoresis | 18 |
health problem | 18 |
pv pa | 18 |
group consisted | 18 |
probably due | 18 |
time point | 18 |
patients requiring | 18 |
escherichia coli | 18 |
also showed | 18 |
higher prevalence | 18 |
creatinine levels | 18 |
autosomal dominant | 18 |
renal tissue | 18 |
binding protein | 18 |
sequential organ | 18 |
internal medicine | 18 |
male wistar | 18 |
elevated levels | 18 |
major abdominal | 18 |
patients hospitalized | 18 |
gold standard | 18 |
also observed | 18 |
high crp | 18 |
biopsy showed | 18 |
may provide | 18 |
laboratory parameters | 18 |
febrile illness | 17 |
streptococcus pneumoniae | 17 |
cecal ligation | 17 |
fold increase | 17 |
severity score | 17 |
group showed | 17 |
glycaemic control | 17 |
well established | 17 |
lower levels | 17 |
taken together | 17 |
high serum | 17 |
may reflect | 17 |
mast cells | 17 |
virus infection | 17 |
common complication | 17 |
relative risk | 17 |
beta cell | 17 |
prognostic factors | 17 |
patient care | 17 |
higher rate | 17 |
severe patients | 17 |
pressure support | 17 |
plasma concentration | 17 |
glucose concentration | 17 |
study aims | 17 |
rat model | 17 |
shed blood | 17 |
lateral flow | 17 |
mean value | 17 |
low levels | 17 |
combination therapy | 17 |
environmental factors | 17 |
nephritic syndrome | 17 |
even though | 17 |
aldosterone levels | 17 |
patients whose | 17 |
renal functions | 17 |
key role | 17 |
lowe syndrome | 17 |
clinical status | 17 |
first months | 17 |
proximal tubular | 17 |
lung cancer | 17 |
mrna levels | 17 |
episodes diagnosed | 17 |
gas exchange | 17 |
extracorporeal membrane | 17 |
induced lung | 17 |
group iii | 17 |
pediatric renal | 17 |
medical history | 17 |
uk biobank | 17 |
treated group | 17 |
data collected | 17 |
blood count | 17 |
emergency room | 17 |
intracranial pressure | 17 |
patients presenting | 17 |
gastric bypass | 17 |
times higher | 17 |
renal survival | 17 |
mass spectrometry | 17 |
significant correlations | 17 |
central role | 17 |
odds ratios | 17 |
experimental group | 17 |
acute coronary | 17 |
cell mass | 17 |
leading cause | 17 |
age groups | 17 |
high glucose | 17 |
risk patients | 17 |
general icu | 17 |
total protein | 17 |
without metabolic | 17 |
phase proteins | 17 |
cx cl | 16 |
tubular cells | 16 |
remained unchanged | 16 |
central nervous | 16 |
steroid sensitive | 16 |
randomly assigned | 16 |
early stage | 16 |
neutrophil activation | 16 |
main cause | 16 |
first day | 16 |
liver function | 16 |
cross sectional | 16 |
lipid metabolism | 16 |
patient outcome | 16 |
cell activation | 16 |
pulmonary infiltrate | 16 |
significant risk | 16 |
cutoff value | 16 |
matched controls | 16 |
patients included | 16 |
tubular function | 16 |
glasgow coma | 16 |
major role | 16 |
shock patients | 16 |
independent variables | 16 |
patient survival | 16 |
anthropometric measurements | 16 |
health organization | 16 |
innate immunity | 16 |
hemolytic uremic | 16 |
two weeks | 16 |
last years | 16 |
failure due | 16 |
diagnostic accuracy | 16 |
severe infection | 16 |
neutrophil count | 16 |
innate immune | 16 |
roc curves | 16 |
renal artery | 16 |
assess whether | 16 |
serum uric | 16 |
potential therapeutic | 16 |
retrospectively reviewed | 16 |
low hdl | 16 |
positively associated | 16 |
general population | 16 |
considered significant | 16 |
csa treatment | 16 |
type i | 16 |
whitney test | 16 |
multiple regression | 16 |
cell function | 16 |
idiopathic nephrotic | 16 |
control subjects | 16 |
elevated serum | 16 |
plasma endotoxin | 16 |
antibiotic prescription | 16 |
fluid balance | 16 |
many studies | 16 |
cancer patients | 16 |
common cold | 16 |
glucose homeostasis | 16 |
data analysis | 16 |
nursing staff | 16 |
severe trauma | 16 |
icu length | 16 |
multivariate logistic | 16 |
reference interval | 16 |
ischemia reperfusion | 16 |
controlled study | 16 |
overweight obesity | 16 |
surgical trauma | 16 |
pseudomonas aeruginosa | 15 |
serum biochemical | 15 |
serum calcium | 15 |
stroke volume | 15 |
group patients | 15 |
test line | 15 |
receptor expression | 15 |
one hour | 15 |
older age | 15 |
angiotensin ii | 15 |
blood sampling | 15 |
study conducted | 15 |
without ms | 15 |
oral prednisone | 15 |
serum cholesterol | 15 |
cholesterol levels | 15 |
mean body | 15 |
postoperative complications | 15 |
airway management | 15 |
one week | 15 |
may explain | 15 |
routine laboratory | 15 |
acute physiology | 15 |
consecutive days | 15 |
showed higher | 15 |
clinical symptoms | 15 |
tissue oxygenation | 15 |
patients infected | 15 |
clinical manifestations | 15 |
insulin therapy | 15 |
diabetic rats | 15 |
septic complications | 15 |
mean values | 15 |
liver enzymes | 15 |
following trauma | 15 |
respiratory infection | 15 |
positive results | 15 |
medical treatment | 15 |
tubular atrophy | 15 |
randomized clinical | 15 |
resistant nephrotic | 15 |
blood urea | 15 |
evaluated using | 15 |
remains unclear | 15 |
chronic allograft | 15 |
gene encoding | 15 |
recent years | 15 |
coma scale | 15 |
improved survival | 15 |
serum insulin | 15 |
two cases | 15 |
cultured cells | 15 |
kg bw | 15 |
growth factors | 15 |
wide range | 15 |
light microscopy | 15 |
prospectively collected | 15 |
grade i | 15 |
several studies | 15 |
normally distributed | 15 |
crp concentrations | 15 |
protective effects | 15 |
also increased | 15 |
tnf levels | 15 |
signal transduction | 15 |
renal allograft | 15 |
renal scars | 15 |
patients will | 15 |
year mortality | 15 |
severe cases | 15 |
pressure measurements | 15 |
three days | 15 |
inflammatory bowel | 15 |
respiratory symptoms | 15 |
previous study | 15 |
version posted | 15 |
hydrogen peroxide | 14 |
nphs mutations | 14 |
fresh frozen | 14 |
febrile patients | 14 |
primary endpoint | 14 |
mechanisms underlying | 14 |
crp mg | 14 |
urinary ph | 14 |
hip ratio | 14 |
protein expression | 14 |
increased serum | 14 |
respiratory support | 14 |
reference values | 14 |
medical intensive | 14 |
plasma level | 14 |
elevated plasma | 14 |
elevated renin | 14 |
patient characteristics | 14 |
combined therapy | 14 |
two days | 14 |
age matched | 14 |
treated rats | 14 |
showed significantly | 14 |
bowel disease | 14 |
free radical | 14 |
media thickness | 14 |
icu staff | 14 |
important cause | 14 |
term survival | 14 |
ten patients | 14 |
genomic dna | 14 |
treatment period | 14 |
patients presented | 14 |
hemodynamic parameters | 14 |
chi square | 14 |
significant negative | 14 |
urinary nag | 14 |
transforming growth | 14 |
surgical treatment | 14 |
glomerular disease | 14 |
high concentrations | 14 |
immune complex | 14 |
endotoxin levels | 14 |
interstitial nephritis | 14 |
may represent | 14 |
clinical parameters | 14 |
neutrophil counts | 14 |
optimal cut | 14 |
southeast asia | 14 |
disseminated intravascular | 14 |
rank test | 14 |
progressive renal | 14 |
grant acknowledgment | 14 |
double blind | 14 |
artery bypass | 14 |
glucose control | 14 |
flow rate | 14 |
patients compared | 14 |
first study | 14 |
enrolled patients | 14 |
dysfunction syndrome | 14 |
serum glucose | 14 |
hospital length | 14 |
severe clinical | 14 |
surgical intensive | 14 |
frozen plasma | 14 |
metabolic alkalosis | 14 |
plasma membrane | 14 |
preliminary data | 14 |
primary vur | 14 |
carotid artery | 14 |
calculated using | 14 |
mosm kg | 14 |
response rate | 14 |
oxygen radicals | 14 |
potential role | 14 |
remained stable | 14 |
long pentraxin | 14 |
body size | 14 |
nphs gene | 14 |
among children | 14 |
early stages | 14 |
age range | 14 |
lymphocyte ratio | 14 |
peritoneal cavity | 14 |
grade vur | 14 |
interstitial lung | 14 |
six months | 14 |
serum concentration | 14 |
compared using | 14 |
diagnostic value | 14 |
serum level | 14 |
transcription factor | 14 |
cardiopulmonary resuscitation | 14 |
cardiovascular mortality | 14 |
calcium excretion | 14 |
chronic inflammation | 14 |
defined according | 14 |
therapeutic approaches | 14 |
vur grade | 14 |
vascular permeability | 14 |
immunosuppressive treatment | 14 |
phase protein | 14 |
months post | 14 |
clinical use | 14 |
oxygen consumption | 14 |
new therapeutic | 14 |
tertiary care | 14 |
energy intake | 14 |
may cause | 13 |
vitro studies | 13 |
systemic vascular | 13 |
baseline values | 13 |
sofa scores | 13 |
allograft nephropathy | 13 |
cell counts | 13 |
time period | 13 |
insulin resistant | 13 |
impaired fasting | 13 |
following injury | 13 |
clinical study | 13 |
patients diagnosed | 13 |
enzyme inhibitors | 13 |
male patients | 13 |
tubular acidosis | 13 |
electronic health | 13 |
low density | 13 |
oxide synthase | 13 |
required intubation | 13 |
egfr sch | 13 |
three months | 13 |
tubular dysfunction | 13 |
per group | 13 |
left atrial | 13 |
risk assessment | 13 |
following major | 13 |
patient outcomes | 13 |
fanconi syndrome | 13 |
women aged | 13 |
schwartz formula | 13 |
cell cycle | 13 |
inverse correlation | 13 |
sham operation | 13 |
first years | 13 |
negatively correlated | 13 |
collected data | 13 |
complete blood | 13 |
major risk | 13 |
vo max | 13 |
blood tests | 13 |
serum sodium | 13 |
kg hr | 13 |
descriptive study | 13 |
serum crp | 13 |
positive cells | 13 |
serum lactate | 13 |
postoperative day | 13 |
protein kinase | 13 |
mean time | 13 |
incidence rate | 13 |
one group | 13 |
free fatty | 13 |
plasma renin | 13 |
lv function | 13 |
muscle mass | 13 |
renal ultrasound | 13 |
effective treatment | 13 |
vital signs | 13 |
immunosuppressive therapy | 13 |
immune parameters | 13 |
patient population | 13 |
significant changes | 13 |
alcohol consumption | 13 |
urinary excretion | 13 |
diffuse mesangial | 13 |
rats subjected | 13 |
showed increased | 13 |
fat percentage | 13 |
graft failure | 13 |
contact system | 13 |
homeostasis model | 13 |
results obtained | 13 |
severe renal | 13 |
community acquired | 13 |
mixed venous | 13 |
factor alpha | 13 |
clinical severity | 13 |
higher level | 13 |
gfr ml | 13 |
data suggests | 13 |
descriptive statistics | 13 |
lipid profiles | 13 |
increased plasma | 13 |
also determined | 13 |
high density | 13 |
lps concentrations | 13 |
granulocyte colony | 13 |
viral load | 13 |
levels may | 13 |
mesangial cells | 13 |
patient groups | 13 |
secondary outcomes | 13 |
intravenous anakinra | 13 |
clinical evaluation | 13 |
activated neutrophils | 13 |
first report | 13 |
antimicrobial therapy | 13 |
stem cells | 13 |
direct correlation | 13 |
cardiometabolic risk | 13 |
therapeutic intervention | 13 |
early postoperative | 13 |
immune responses | 13 |
oxidative damage | 13 |
chest radiograph | 13 |
oxygen therapy | 13 |
normal saline | 13 |
macroscopic hematuria | 13 |
circadian rhythm | 13 |
adult respiratory | 13 |
urinary calcium | 13 |
within months | 13 |
first week | 13 |
plasma creatinine | 13 |
aromatic plants | 13 |
surgical icu | 13 |
skin lesions | 13 |
multivariable logistic | 13 |
genes involved | 13 |
past years | 13 |
median values | 13 |
renal development | 12 |
alkaline phosphatase | 12 |
remains unknown | 12 |
wild type | 12 |
data demonstrate | 12 |
neutrophil gelatinase | 12 |
without renal | 12 |
lps administration | 12 |
febrile children | 12 |
coronary heart | 12 |
acute liver | 12 |
tnf mab | 12 |
control rats | 12 |
group without | 12 |
i levels | 12 |
study demonstrates | 12 |
blood gases | 12 |
one month | 12 |
purpura nephritis | 12 |
hazard ratio | 12 |
daily drug | 12 |
kinderen met | 12 |
primary disease | 12 |
neurological recovery | 12 |
receive either | 12 |
muscle cells | 12 |
administering dexmedetomidine | 12 |
barrier function | 12 |
two hours | 12 |
small number | 12 |
hong kong | 12 |
heavy proteinuria | 12 |
recurrent uti | 12 |
acute onset | 12 |
high sensitivity | 12 |
overall mortality | 12 |
control values | 12 |
kidney failure | 12 |
spontaneous circulation | 12 |
normal wbc | 12 |
superoxide dismutase | 12 |
studies using | 12 |
retrospective observational | 12 |
increased levels | 12 |
normal levels | 12 |
nosocomial infections | 12 |
may influence | 12 |
fractional excretion | 12 |
data show | 12 |
reference range | 12 |
pediatric population | 12 |
anthropometric data | 12 |
positive predictive | 12 |
crp may | 12 |
wilms tumor | 12 |
previous reports | 12 |
identify patients | 12 |
fluid administration | 12 |
prognostic marker | 12 |
burned patients | 12 |
subjects without | 12 |
continuous infusion | 12 |
pressure monitoring | 12 |
ace inhibitors | 12 |
venous catheter | 12 |
tnf receptors | 12 |
patients may | 12 |
intrauterine growth | 12 |
infectious origin | 12 |
pcr amplification | 12 |
cause mortality | 12 |
protein level | 12 |
vf vt | 12 |
vascular endothelial | 12 |
magnetic resonance | 12 |
peak temperature | 12 |
patient group | 12 |
post transplant | 12 |
associated lipocalin | 12 |
systemic lupus | 12 |
severely ill | 12 |
respiratory infections | 12 |
collagen type | 12 |
mesangial proliferation | 12 |
dose dependent | 12 |
hiv infection | 12 |
data obtained | 12 |
stage ii | 12 |
studies showed | 12 |
least two | 12 |
van een | 12 |
bl mice | 12 |
oxygen debt | 12 |
inflammatory processes | 12 |
medical care | 12 |
normal serum | 12 |
analysis using | 12 |
following hs | 12 |
inhibitory effect | 12 |
parenteral nutrition | 12 |
cell lines | 12 |
systemic circulation | 12 |
het protocol | 12 |
using standard | 12 |
dry weight | 12 |
physical inactivity | 12 |
patients following | 12 |
additional file | 12 |
current study | 12 |
day post | 12 |
metabolic parameters | 12 |
intravascular coagulation | 12 |
higher values | 12 |
systolic bp | 12 |
inflammatory diseases | 12 |
protein synthesis | 12 |
clot microstructure | 12 |
apparently healthy | 12 |
also detected | 12 |
small intestine | 12 |
liver injury | 12 |
higher incidence | 12 |
gestational diabetes | 12 |
relapse rate | 12 |
undergoing cardiac | 12 |
male gender | 12 |
phagocytic cells | 12 |
icu population | 12 |
oral cyclophosphamide | 12 |
identified patients | 12 |
experimental studies | 12 |
induced cytokine | 12 |
marginal structural | 12 |
detection limit | 12 |
glucose uptake | 12 |
significantly less | 12 |
albumin creatinine | 12 |
significant morbidity | 12 |
valve disease | 12 |
crp value | 12 |
natural history | 11 |
group iv | 11 |
bacterial growth | 11 |
first line | 11 |
nk cells | 11 |
toxic effects | 11 |
previously described | 11 |
adiponectin levels | 11 |
early albumin | 11 |
still alive | 11 |
deficient mice | 11 |
normal limits | 11 |
improve survival | 11 |
signaling pathways | 11 |
tnf release | 11 |
bartter syndrome | 11 |
moderate covid | 11 |
likely due | 11 |
increased expression | 11 |
poorly understood | 11 |
health status | 11 |
human monocytes | 11 |
lymphocyte count | 11 |
study examined | 11 |
patients enrolled | 11 |
airway pressure | 11 |
significant higher | 11 |
surgical procedures | 11 |
oxygen free | 11 |
increased compared | 11 |
study protocol | 11 |
rhgh therapy | 11 |
possible role | 11 |
cd ratio | 11 |
low birth | 11 |
vasopressor support | 11 |
emergency medicine | 11 |
ob ob | 11 |
insulin level | 11 |
traumatic injury | 11 |
matched healthy | 11 |
nasopharyngeal swab | 11 |
posted june | 11 |
ill patient | 11 |
hours following | 11 |
months old | 11 |
among subjects | 11 |
side effect | 11 |
received either | 11 |
initial cardiac | 11 |
energy metabolism | 11 |
also associated | 11 |
glyceamic control | 11 |
bnp value | 11 |
cardiogenic shock | 11 |
kg i | 11 |
lps injection | 11 |
left ventricle | 11 |
urotensin ii | 11 |
immunosuppressive drugs | 11 |
fasting serum | 11 |
ko mice | 11 |
lung infiltrates | 11 |
cd cell | 11 |
trough level | 11 |
pulmonary hypertension | 11 |
glucose tolerant | 11 |
estimated gfr | 11 |
ureteric bud | 11 |
kidney diseases | 11 |
cd expression | 11 |
ischemic heart | 11 |
mouse model | 11 |
survival analysis | 11 |
pulmonary vascular | 11 |
dr expression | 11 |
receptor blockers | 11 |
red cell | 11 |
biopsy specimens | 11 |
multiorgan failure | 11 |
following treatment | 11 |
genetic factors | 11 |
twice daily | 11 |
function parameters | 11 |
infusion rate | 11 |
rs polymorphism | 11 |
pi concentrations | 11 |
good outcome | 11 |
metabolic rate | 11 |
gut barrier | 11 |
obstructive uropathy | 11 |
oxygen species | 11 |
pulmonary infection | 11 |
kg body | 11 |
core temperature | 11 |
blood vessels | 11 |
last follow | 11 |
tissue hypoxia | 11 |
significantly older | 11 |
significant role | 11 |
group treated | 11 |
enteral nutrition | 11 |
graft loss | 11 |
low molecular | 11 |
final outcome | 11 |
normal dogs | 11 |
western blotting | 11 |
ventricular mass | 11 |
tyrosine kinase | 11 |
pulse wave | 11 |
serum ferritin | 11 |
diagnostic tests | 11 |
soluble tnf | 11 |
ae mg | 11 |
month follow | 11 |
vascular smooth | 11 |
chronic dysglycemia | 11 |
premature infants | 11 |
therapy may | 11 |
aortic valve | 11 |
mental retardation | 11 |
depressive symptoms | 11 |
classified according | 11 |
kg iv | 11 |
renal stones | 11 |
significant change | 11 |
examination revealed | 11 |
also investigated | 11 |
lower urinary | 11 |
target temperature | 11 |
fluid responsiveness | 11 |
improved significantly | 11 |
caloric intake | 11 |
cmv infection | 11 |
nasal cannula | 11 |
homa index | 11 |
change significantly | 11 |
non diabetic | 11 |
essential hypertension | 11 |
mesenteric lymph | 11 |
wave velocity | 11 |
year follow | 11 |
clinical setting | 11 |
acute stage | 11 |
bacterial challenge | 11 |
ca i | 11 |
mean number | 11 |
prognostic factor | 11 |
cr ratio | 11 |
mainly due | 11 |
lithium chloride | 11 |
tbi patients | 11 |
direct sequencing | 11 |
bnp levels | 11 |
angiotensin system | 11 |
high incidence | 11 |
visceral adipose | 11 |
prospectively studied | 11 |
atrial natriuretic | 11 |
early intervention | 11 |
experimental model | 11 |
structural models | 11 |
sensitive nephrotic | 11 |
end point | 11 |
triglyceride levels | 11 |
experimental models | 11 |
rehabilitation program | 10 |
also reduced | 10 |
clinical significance | 10 |
ards patients | 10 |
frequently associated | 10 |
fluid intake | 10 |
alternate day | 10 |
also evaluated | 10 |
body height | 10 |
ecmo support | 10 |
subcutaneous adipose | 10 |
right ventricular | 10 |
correlated well | 10 |
wilcoxon test | 10 |
sepsis onset | 10 |
canine cp | 10 |
small vessels | 10 |
coronary syndromes | 10 |
broad spectrum | 10 |
expression levels | 10 |
requiring mechanical | 10 |
research design | 10 |
control mice | 10 |
endotracheal tube | 10 |
low serum | 10 |
steroid withdrawal | 10 |
ms ms | 10 |
mild renal | 10 |
myocardial ischemia | 10 |
capillary permeability | 10 |
royal canin | 10 |
ambulatory blood | 10 |
may improve | 10 |
diastolic dysfunction | 10 |
admitted patients | 10 |
mean serum | 10 |
bacterial clearance | 10 |
results may | 10 |
positive blood | 10 |
right kidney | 10 |
study including | 10 |
ae kg | 10 |
morphological changes | 10 |
endotoxin infusion | 10 |
burn patients | 10 |
antenatal hydronephrosis | 10 |
cytokine response | 10 |
phase response | 10 |
medical school | 10 |
pulmonary embolism | 10 |
gastrointestinal disease | 10 |
living related | 10 |
identified using | 10 |
rate variability | 10 |
colony stimulating | 10 |
also assessed | 10 |
peer review | 10 |
fat oxidation | 10 |
small sample | 10 |
ferritin levels | 10 |
severe tbi | 10 |
invoering van | 10 |
sodium chloride | 10 |
pivotal role | 10 |
virus detection | 10 |
prospective clinical | 10 |
detected using | 10 |
calorie diet | 10 |
hospital acquired | 10 |
pulmonary infiltrates | 10 |
vap incidence | 10 |
oxygen extraction | 10 |
randomized study | 10 |
induced shock | 10 |
treatment modality | 10 |
bmi th | 10 |
exocrine pancreatic | 10 |
type dm | 10 |
children received | 10 |
wbc counts | 10 |
active phase | 10 |
progenitor cells | 10 |
malignant neoplasm | 10 |
lps stimulation | 10 |
apache score | 10 |
sham group | 10 |
positive effect | 10 |
limited data | 10 |
owned dogs | 10 |
serum ca | 10 |
bone age | 10 |
one patients | 10 |
upper limit | 10 |
normal human | 10 |
one third | 10 |
initial presentation | 10 |
associated complications | 10 |
positive association | 10 |
endothelial function | 10 |
hepatic steatosis | 10 |
sleep deprivation | 10 |
blood specimens | 10 |
ventilator days | 10 |
health record | 10 |
tumour necrosis | 10 |
transplanted patients | 10 |
treated mice | 10 |
reverse transcription | 10 |
kupffer cells | 10 |
plasminogen activator | 10 |
within normal | 10 |
frequent complication | 10 |
significant relationship | 10 |
care setting | 10 |
corticosteroid therapy | 10 |
treatment protocol | 10 |
total rna | 10 |
human neutrophils | 10 |
therapeutic range | 10 |
atp iii | 10 |
mortality risk | 10 |
continuous monitoring | 10 |
leukocyte adhesion | 10 |
study provides | 10 |
plasma tnf | 10 |
gene mutation | 10 |
following severe | 10 |
mitral regurgitation | 10 |
crf patients | 10 |
support ventilation | 10 |
center study | 10 |
examined patients | 10 |
immune cell | 10 |
healthy age | 10 |
mean apache | 10 |
circadian clock | 10 |
respiratory disease | 10 |
adverse effect | 10 |
bacterial sepsis | 10 |
endotoxin induced | 10 |
statistically different | 10 |
using spss | 10 |
proliferative glomerulonephritis | 10 |
prospective randomized | 10 |
bmi kg | 10 |
findings support | 10 |
serum citrulline | 10 |
among women | 10 |
single dose | 10 |
breed dogs | 10 |
angiotensinogen gene | 10 |
following parameters | 10 |
randomised controlled | 10 |
cytosolic ca | 10 |
staphylococcus aureus | 10 |
high affinity | 10 |
cretan aromatic | 10 |
antithrombin iii | 10 |
also decreased | 10 |
iga deposition | 10 |
biopsy specimen | 10 |
chronic af | 10 |
tg mice | 10 |
useful tool | 10 |
success rate | 10 |
glucose concentrations | 10 |
emergency departments | 10 |
vitro experiments | 10 |
supplemental oxygen | 10 |
aldosterone system | 10 |
chronic obstructive | 10 |
thrombotic microangiopathy | 10 |
underlying diseases | 10 |
biopsy proven | 10 |
muscle membrane | 10 |
icp monitoring | 10 |
obstructive pulmonary | 10 |
icu los | 10 |
non invasive | 10 |
roc analysis | 10 |
congenital nephrotic | 10 |
pulse therapy | 10 |
observational cohort | 10 |
thrombin generation | 10 |
ventricular hypertrophy | 10 |
clinical information | 10 |
cd ro | 10 |
potential risk | 10 |
steroid resistance | 10 |
renal blood | 10 |
surgical complications | 10 |
differed significantly | 10 |
rv function | 10 |
mcg kg | 10 |
following cardiac | 10 |
abdominal ultrasound | 10 |
medical management | 10 |
without significant | 10 |
case series | 10 |
medical sciences | 10 |
randomly divided | 10 |
disease onset | 10 |
uv exposure | 10 |
better understanding | 10 |
sustained remission | 10 |
organ system | 10 |
severe bacterial | 10 |
pulse contour | 10 |
chronic heart | 10 |
elisa kit | 10 |
per year | 10 |
com scientificreports | 10 |
scrub typhus | 10 |
virus infections | 10 |
tlr ko | 10 |
days following | 10 |
per se | 10 |
therapeutic interventions | 10 |
xanthine oxidase | 10 |
plasma il | 10 |
common clinical | 10 |
renal histology | 10 |
gas analysis | 10 |
progressive disease | 10 |
better outcome | 10 |
week period | 10 |
per week | 9 |
two months | 9 |
chart review | 9 |
multiple logistic | 9 |
genetic analysis | 9 |
higher serum | 9 |
lower risk | 9 |
retrospectively studied | 9 |
control dogs | 9 |
renal size | 9 |
blood coagulation | 9 |
school children | 9 |
family satisfaction | 9 |
therapeutic agents | 9 |
cell apoptosis | 9 |
pulse pressure | 9 |
iu kg | 9 |
resistant ns | 9 |
acute care | 9 |
normal body | 9 |
trough levels | 9 |
may suggest | 9 |
considered statistically | 9 |
renal units | 9 |
test results | 9 |
chronic inflammatory | 9 |
hemoperfusion cartridge | 9 |
following hemorrhage | 9 |
mg mg | 9 |
clinically significant | 9 |
tnf receptor | 9 |
critical role | 9 |
medication errors | 9 |
cardiac rhythm | 9 |
high plasma | 9 |
lactate levels | 9 |
surgical procedure | 9 |
eleven patients | 9 |
hepatic function | 9 |
ordinal scale | 9 |
renal pelvis | 9 |
hoc analysis | 9 |
class iii | 9 |
phagocytic activity | 9 |
wt mice | 9 |
ii scores | 9 |
low concentrations | 9 |
early phase | 9 |
tocilizumab use | 9 |
examination showed | 9 |
cells may | 9 |
average values | 9 |
phosphate binders | 9 |
operated rats | 9 |
human immune | 9 |
nd group | 9 |
ecmo circuit | 9 |
like growth | 9 |
chronic health | 9 |
abscess formation | 9 |
may benefit | 9 |
illness severity | 9 |
young children | 9 |
male female | 9 |
research institute | 9 |
serum adiponectin | 9 |
intestinal mucosal | 9 |
homocysteine levels | 9 |
pon activity | 9 |
smoking status | 9 |
missense mutations | 9 |
received mg | 9 |
early marker | 9 |
therapeutic options | 9 |
ulcer prophylaxis | 9 |
venous pressure | 9 |
increased use | 9 |
endotoxin shock | 9 |
resistance index | 9 |
evidence suggests | 9 |
grade ii | 9 |
induced tnf | 9 |
kidney volume | 9 |
five years | 9 |
mean bmi | 9 |
inflammatory conditions | 9 |
crucial role | 9 |
patients vs | 9 |
circadian rhythms | 9 |
high volume | 9 |
phase ii | 9 |
inflammatory biomarker | 9 |
inflammatory status | 9 |
multivariate regression | 9 |
transcription factors | 9 |
albumin levels | 9 |
chest tube | 9 |
otherwise healthy | 9 |
diseases including | 9 |
neurologic outcome | 9 |
mm edta | 9 |
higher proportion | 9 |
inflammatory effects | 9 |
seven days | 9 |
died within | 9 |
wet nights | 9 |
also performed | 9 |
early post | 9 |
fecal iga | 9 |
term prognosis | 9 |
confounding factors | 9 |
mean blood | 9 |
reduced mortality | 9 |
secondary outcome | 9 |
allogeneic blood | 9 |
future studies | 9 |
renal cortex | 9 |
inflammatory cytokine | 9 |
consecutively admitted | 9 |
high proportion | 9 |
porcine model | 9 |
flow nasal | 9 |
described previously | 9 |
data support | 9 |
renal graft | 9 |
controlled trials | 9 |
defense mechanisms | 9 |
liver cirrhosis | 9 |
pda closure | 9 |
blind study | 9 |
glomerular basement | 9 |
female gender | 9 |
highly correlated | 9 |
two decades | 9 |
polycystic kidney | 9 |
cardiovascular system | 9 |
na seo | 9 |
situ hybridization | 9 |
antibody titres | 9 |
femoral artery | 9 |
sublingual microcirculation | 9 |
study participants | 9 |
gap junctions | 9 |
serum tnf | 9 |
insurance company | 9 |
facs analysis | 9 |
low grade | 9 |
disorder characterized | 9 |
blood volume | 9 |
respiratory effort | 9 |
months period | 9 |
may present | 9 |
recurrent urinary | 9 |
pancreatic islets | 9 |
normal group | 9 |
life threatening | 9 |
dogs diagnosed | 9 |
blot analysis | 9 |
ml respectively | 9 |
synthesis inhibitor | 9 |
lps group | 9 |
study investigated | 9 |
control patients | 9 |
important mediator | 9 |
increased susceptibility | 9 |
mean gfr | 9 |
kans op | 9 |
first episode | 9 |
bolus injection | 9 |
pregnant women | 9 |
child health | 9 |
risk group | 9 |
cellular immune | 9 |
therapeutic target | 9 |
animals received | 9 |
reduced glutathione | 9 |
condition score | 9 |
serum iron | 9 |
phase reaction | 9 |
th month | 9 |
hepatic failure | 9 |
immunohistochemical staining | 9 |
lysosomal enzymes | 9 |
aki patients | 9 |
median value | 9 |
multidisciplinary team | 9 |
release syndrome | 9 |
plasma insulin | 9 |
correlation analysis | 9 |
therapeutic strategy | 9 |
chronic dialysis | 9 |
clinical condition | 9 |
wallis test | 9 |
quantitative pcr | 9 |
mg protein | 9 |
treated groups | 9 |
obese individuals | 9 |
least months | 9 |
lupus erythematosus | 9 |
many patients | 9 |
alcoholic fatty | 9 |
way anova | 9 |
strain rate | 9 |
data showed | 9 |
base excess | 9 |
soluble form | 9 |
patients using | 9 |
urine sample | 9 |
feedback function | 9 |
tubular epithelial | 9 |
verrichten van | 9 |
higher bmi | 9 |
closely related | 9 |
one episode | 9 |
measured daily | 9 |
steroid treatment | 9 |
cardiac arrests | 9 |
bone disease | 9 |
normal controls | 9 |
showed similar | 9 |
mean sem | 9 |
vivo studies | 9 |
anthropometric measures | 9 |
deleterious effects | 9 |
patient data | 9 |
myocardial injury | 9 |
less frequently | 9 |
height ratio | 9 |
tyrosine phosphorylation | 9 |
supplemental table | 9 |
healthy donors | 9 |
urine ph | 9 |
change disease | 9 |
blood stream | 9 |
tubular necrosis | 9 |
surface markers | 9 |
disease process | 9 |
creatinine ratios | 9 |
inflammatory cells | 9 |
outcome data | 9 |
macrophage activation | 9 |
human il | 9 |
two types | 9 |
grading system | 9 |
het verrichten | 9 |
patients years | 9 |
experimental animals | 9 |
greater risk | 9 |
function following | 9 |
patient developed | 9 |
also known | 9 |
een rs | 9 |
elective surgery | 9 |
repeated measures | 9 |
acid creatinine | 9 |
spontaneous breathing | 9 |
sepsis model | 9 |
initial rhythm | 9 |
van antibiotica | 9 |
lean body | 9 |
like peptide | 9 |
prostaglandin synthesis | 9 |
characteristic curve | 9 |
early warning | 9 |
baseline levels | 9 |
weight reduction | 9 |
heart surgery | 9 |
glutathione peroxidase | 9 |
placebo controlled | 9 |
underlying mechanisms | 9 |
results support | 9 |
took place | 9 |
secondary hyperparathyroidism | 9 |
new onset | 9 |
diagnosed according | 9 |
het aantal | 9 |
provide evidence | 9 |
findings indicate | 9 |
either group | 9 |
hemolytic anemia | 9 |
diabetic children | 9 |
may reduce | 9 |
different time | 9 |
hfd myr | 9 |
successfully treated | 9 |
clinical findings | 9 |
subarachnoid hemorrhage | 9 |
pleural effusions | 9 |
remaining patients | 9 |
mixed icu | 9 |
drug cost | 9 |
main group | 9 |
lactic acid | 9 |
education program | 9 |
significant impact | 9 |
mice fed | 9 |
may act | 9 |
significant effect | 9 |
hours post | 9 |
class i | 9 |
two hundred | 9 |
currently available | 9 |
lactate dehydrogenase | 9 |
also compared | 9 |
ng gwt | 9 |
vitro stimulation | 9 |
data regarding | 9 |
rare disease | 9 |
valve repair | 8 |
mean height | 8 |
organ failures | 8 |
anthropometric parameters | 8 |
last year | 8 |
radiologically confirmed | 8 |
antibody titers | 8 |
glycosylated hemoglobin | 8 |
prenatal diagnosis | 8 |
sore throat | 8 |
biological effects | 8 |
multicenter study | 8 |
mutant allele | 8 |
superior mesenteric | 8 |
levels compared | 8 |
iq range | 8 |
producing cells | 8 |
pts admitted | 8 |
soft tissue | 8 |
significant cad | 8 |
levels decreased | 8 |
using flow | 8 |
thalassemia major | 8 |
proteinase inhibitor | 8 |
study groups | 8 |
well described | 8 |
renin levels | 8 |
crp concentration | 8 |
patients suffered | 8 |
mean sd | 8 |
beta cells | 8 |
pulmonary fibrosis | 8 |
using elisa | 8 |
factors may | 8 |
acute dyspnea | 8 |
st group | 8 |
identifying patients | 8 |
based study | 8 |
groups received | 8 |
veterinary medicine | 8 |
inflammatory protein | 8 |
predictive values | 8 |
obese group | 8 |
cell injury | 8 |
within minutes | 8 |
endotoxic shock | 8 |
continuous data | 8 |
shockable rhythm | 8 |
normal population | 8 |
evaluate whether | 8 |
radical production | 8 |
sas institute | 8 |
new biomarkers | 8 |
baseline risk | 8 |
significantly improve | 8 |
prone positioning | 8 |
nitrogen balance | 8 |
may therefore | 8 |
antihypertensive drugs | 8 |
training program | 8 |
may serve | 8 |
stress ulcers | 8 |
mediator release | 8 |
increased cardiac | 8 |
bacterial meningitis | 8 |
indian subset | 8 |
troponin i | 8 |
autologous blood | 8 |
germany critical | 8 |
patient received | 8 |
binary logistic | 8 |
developing countries | 8 |
type alpha | 8 |
national cholesterol | 8 |
one dog | 8 |
febrile uti | 8 |
matrix proteins | 8 |
behandeling van | 8 |
sample collection | 8 |
chronic liver | 8 |
blood pressures | 8 |
carbon dioxide | 8 |
patients also | 8 |
increased urinary | 8 |
much higher | 8 |
may indicate | 8 |
cardiovascular morbidity | 8 |
nephrotic proteinuria | 8 |
mesenteric artery | 8 |
pentraxin ptx | 8 |
uv light | 8 |
operating characteristics | 8 |
daily living | 8 |
mpo activity | 8 |
full thickness | 8 |
carotid arteries | 8 |
ill septic | 8 |
retrospective audit | 8 |
bypass grafting | 8 |
false positive | 8 |
alanine aminotransferase | 8 |
overall survival | 8 |
diabetic cardiomyopathy | 8 |
clinical syndrome | 8 |
pediatric nephrologists | 8 |
may increase | 8 |
three dogs | 8 |
type iv | 8 |
fluid removal | 8 |
intestinal transit | 8 |
renal biopsies | 8 |
esicm annual | 8 |
clinical variables | 8 |
procalcitonin levels | 8 |
recently shown | 8 |
lethal dose | 8 |
per hour | 8 |
cell membrane | 8 |
early administration | 8 |
mesothelial cells | 8 |
years ago | 8 |
family medicine | 8 |
dna binding | 8 |
hospital care | 8 |
prediction model | 8 |
wilcoxon signed | 8 |
tap water | 8 |
intestinal mucosa | 8 |
linear mixed | 8 |
initial therapy | 8 |
randomly allocated | 8 |
may affect | 8 |
operation group | 8 |
three children | 8 |
ischemic stroke | 8 |
first three | 8 |
higher percentage | 8 |
biochemical markers | 8 |
higher compared | 8 |
severe hypertension | 8 |
cerebrospinal fluid | 8 |
transit time | 8 |
resistin gene | 8 |
rd esicm | 8 |
cortisol levels | 8 |
six groups | 8 |
screening test | 8 |
first dose | 8 |
general surgery | 8 |
diastolic pressure | 8 |
liquid chromatography | 8 |
contour analysis | 8 |
circulatory failure | 8 |
jugular vein | 8 |
significantly increase | 8 |
thyroid function | 8 |
earlier studies | 8 |
persistent proteinuria | 8 |
cell viability | 8 |
glomerular diseases | 8 |
dialysis patients | 8 |
physically active | 8 |
septic response | 8 |
severely obese | 8 |
increased odds | 8 |
idiopathic hypercalciuria | 8 |
annual congress | 8 |
medical icu | 8 |
erythrocyte sedimentation | 8 |
healthy adults | 8 |
lower values | 8 |
immune complexes | 8 |
capillary density | 8 |
socioeconomic status | 8 |
scoring systems | 8 |
statistical package | 8 |
graft infection | 8 |
mechanisms involved | 8 |
routine clinical | 8 |
cell tumours | 8 |
tube removal | 8 |
polycystic ovary | 8 |
predictive factors | 8 |
spleen cells | 8 |
renal recovery | 8 |
fluorescence microscopy | 8 |
retrospective review | 8 |
low level | 8 |
carotid intima | 8 |
compound heterozygous | 8 |
mice received | 8 |
conducted using | 8 |
septic group | 8 |
diabetes federation | 8 |
ct scan | 8 |
may develop | 8 |
niv failure | 8 |
three years | 8 |
pressure measurement | 8 |
chest radiographs | 8 |
ohca due | 8 |
every hours | 8 |
increased blood | 8 |
early identification | 8 |
refill time | 8 |
sepsis induction | 8 |
international diabetes | 8 |
table shows | 8 |
pylori infection | 8 |
adrenal medulla | 8 |
operative day | 8 |
randomized trials | 8 |
postoperative analgesia | 8 |
healthy people | 8 |
remission rate | 8 |
clinical diagnosis | 8 |
organ dysfunctions | 8 |
adverse reactions | 8 |
capillary refill | 8 |
high grade | 8 |
first two | 8 |
vascular changes | 8 |
remained significant | 8 |
case reports | 8 |
south africa | 8 |
pneumonia patients | 8 |
general anesthesia | 8 |
investigated patients | 8 |
hd patients | 8 |
recent data | 8 |
endothelial damage | 8 |
reach statistical | 8 |
left kidney | 8 |
day survival | 8 |
excluded patients | 8 |
median icu | 8 |
correlated positively | 8 |
tg kg | 8 |
central hospital | 8 |
ischemia time | 8 |
syndrome patients | 8 |
percutaneous coronary | 8 |
within one | 8 |
data processing | 8 |
sepsis may | 8 |
severe side | 8 |
better indicator | 8 |
serum cobalamin | 8 |
outpatient clinic | 8 |
first group | 8 |
treatment modalities | 8 |
cd ap | 8 |
mortality compared | 8 |
mutant podocin | 8 |
kg per | 8 |
also recorded | 8 |
might explain | 8 |
curve analysis | 8 |
may allow | 8 |
cardiac slices | 8 |
polymorphonuclear leukocytes | 8 |
known risk | 8 |
arterial line | 8 |
reported previously | 8 |
th week | 8 |
associated coagulopathy | 8 |
median survival | 8 |
growth failure | 8 |
found among | 8 |
fed rats | 8 |
cap patients | 8 |
health evaluation | 8 |
intravenous infusion | 8 |
muscle tone | 8 |
proximal tubule | 8 |
high morbidity | 8 |
last decade | 8 |
cancer risk | 8 |
primary end | 8 |
four cases | 8 |
inflammatory reactions | 8 |
results confirm | 8 |
fatal outcome | 8 |
hepatic insulin | 8 |
en behandeling | 8 |
cell damage | 8 |
mg daily | 8 |
tubular injury | 8 |
clcnkb gene | 8 |
institutional review | 8 |
neurological signs | 8 |
less likely | 8 |
sd rats | 8 |
health workers | 8 |
enzyme inhibitor | 8 |
higher body | 8 |
high degree | 8 |
ml vs | 8 |
patients respectively | 8 |
hospital los | 8 |
blood ph | 8 |
vasopressor exposure | 8 |
leisure time | 8 |
paediatric renal | 8 |
clinical utility | 8 |
serum biochemistry | 8 |
atypical hus | 8 |
samples taken | 8 |
haemorrhagic shock | 8 |
examined using | 8 |
glomerular sclerosis | 8 |
inulin clearance | 8 |
developed acute | 8 |
kidney size | 8 |
first weeks | 8 |
studies show | 8 |
squared test | 8 |
gene product | 8 |
improves survival | 8 |
disease characterized | 8 |
resistance training | 8 |
second group | 8 |
muscle strength | 8 |
myocardial function | 8 |
cell dysfunction | 8 |
fio ratio | 8 |
published data | 8 |
mild hypothermia | 8 |
een thoraxfoto | 8 |
meier method | 8 |
positive correlations | 8 |
post lps | 8 |
lost weight | 8 |
increased values | 8 |
early sepsis | 8 |
frequent cause | 8 |
hour urine | 8 |
allograft rejection | 8 |
vascular tone | 8 |
increased il | 8 |
nosocomial infection | 8 |
hypertensive children | 8 |
human umbilical | 8 |
whole study | 8 |
hospital survival | 8 |
dendritic cells | 8 |
surgery patients | 8 |
study involved | 8 |
mean dose | 8 |
monocytes macrophages | 8 |
laboratory abnormalities | 8 |
bacterial cap | 8 |
signaling pathway | 8 |
strong association | 8 |
unclear whether | 8 |
mycoplasma pneumoniae | 8 |
thiobarbituric acid | 8 |
hospital course | 8 |
data available | 8 |
late sepsis | 8 |
pearson correlation | 8 |
elisa method | 8 |